Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109727 | 1.00 | IDO1 (0.47) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL28971366 | 1.00 | IDO1 (0.47) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL5852603 | 1.00 | IDO1 (0.47) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL9492857 | 0.88 | IDO1 (0.50) | IDO1 | |
| SCHEMBL5852536 | 0.88 | IDO1 (0.50) | IDO1 | |
| SCHEMBL8201616 | 0.77 | KMT2A (0.46) | HTR2A | |
| SCHEMBL5061699 | 0.77 | KMT2A (0.46) | HTR2A | |
| SCHEMBL2370159 | 0.77 | KMT2A (0.46) | HTR2A | |
| SCHEMBL2696782 | 0.77 | KMT2A (0.46) | HTR2A | |
| SCHEMBL18650080 | 0.75 | SRD5A1 (0.43) | IDO1PDPK1CYP11B2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5637738-A | Processes for preparing 1,2-epoxy-1,2,3,4-tetrahydronaphthalenes | ZENECA LIMITED (GB) | 1997-06-10 | — | — | US | claimed |
| EP-0686153-B1 | CHEMICAL PROCESS FOR PREPARATION OF 1,2-EPOXY-1,2,3,4-TETRAHYDRNAPHTALENE | ZENECA LTD (GB) | 1997-06-04 | — | — | EP | claimed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| EP-2342178-B1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2016-09-28 | — | — | EP | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-6348608-B1 | ADDING OXIDIZING AGENT TO REACTION SOLUTION COMPRISING CHIRAL CYCLIC ENANTIOMERICALLY ENRICHED KETONE AND OLEFIN UNDER CONDITIONS EFFECTIVE TO GENERATE ENANTIOMERICALLY ENRICHED EPOXIDE, SEPARATING EPOXIDE FROM REACTION SOLUTION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2002-02-19 | — | — | US | disclosed |
| US-5637738-A | Processes for preparing 1,2-epoxy-1,2,3,4-tetrahydronaphthalenes | ZENECA LIMITED (GB) | 1997-06-10 | — | — | US | disclosed |
| US-5637738-A | Processes for preparing 1,2-epoxy-1,2,3,4-tetrahydronaphthalenes | ZENECA LIMITED (GB) | 1997-06-10 | — | — | US | disclosed |
| EP-0686153-B1 | CHEMICAL PROCESS FOR PREPARATION OF 1,2-EPOXY-1,2,3,4-TETRAHYDRNAPHTALENE | ZENECA LTD (GB) | 1997-06-04 | — | — | EP | disclosed |
| EP-0686153-B1 | CHEMICAL PROCESS FOR PREPARATION OF 1,2-EPOXY-1,2,3,4-TETRAHYDRNAPHTALENE | ZENECA LTD (GB) | 1997-06-04 | — | — | EP | disclosed |
| EP-0686153-A1 | CHEMICAL PROCESS | ZENECA LTD (GB) | 1995-12-13 | — | — | EP | disclosed |
| EP-0686153-A1 | CHEMICAL PROCESS | ZENECA LTD (GB) | 1995-12-13 | — | — | EP | disclosed |
| WO-1994019338-A1 | CHEMICAL PROCESS | ZENECA LIMITED (GB) | 1994-09-01 | — | — | WO | disclosed |
| WO-1994019338-A1 | CHEMICAL PROCESS | ZENECA LIMITED (GB) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, PKD1 | IDO1 154/4885PDPK1 2942/4885CYP11B2 23/4885 |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, FANCI | IDO1 115/4885PDPK1 2688/4885CYP11B2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.